Tags

Type your tag names separated by a space and hit enter

Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples.
Metabolites. 2021 May 13; 11(5)M

Abstract

Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines were investigated, in order to identify potential distinguishing markers. Serum samples after use of Sativex®, Dronabinol or medical cannabis were collected and analyzed for 18 different cannabinoids, using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Analytes included delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabicyclol, tetrahydrocannabivarin, cannabidivarin, tetrahydocannabinolic acid A, cannabidiolic acid, cannabinolic acid, cannabigerolic acid, cannabichromenic acid, cannabicyclolic acid, tetrahydrocannabivarinic acid and cannabidivarinic acid. Cannabinoid profiles of study samples were compared to profiles of street cannabis user samples via principal component analysis and Kruskal-Wallis test. Potential distinguishing markers for Dronabinol and Sativex® intake were identified, including 11-hydroxy-tetrahydrocannabinol/delta-9-tetrahydrocannabinol ratios ≥1 and increased concentrations of 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol or cannabichromene. Larger quantities of minor cannabinoids suggested use of cannabis. Use of medical and street cannabis could not be distinguished, except for use of a cannabidiol-rich strain with higher cannabidiol/delta-9-tetrahydrocannabinol and cannabichromene/delta-9-tetrahydrocannabinol ratios. Findings of the study were used to classify forensic serum samples with self-reported use of cannabis-based medicines.

Authors+Show Affiliations

Institute of Legal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Institute of Legal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Institute of Legal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Institute of Legal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Department of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.Institute of Legal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34068332

Citation

Scheunemann, Anne, et al. "Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples." Metabolites, vol. 11, no. 5, 2021.
Scheunemann A, Elsner K, Germerott T, et al. Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. Metabolites. 2021;11(5).
Scheunemann, A., Elsner, K., Germerott, T., Groppa, S., Hess, C., Miederer, I., Poplawski, A., & Röhrich, J. (2021). Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. Metabolites, 11(5). https://doi.org/10.3390/metabo11050316
Scheunemann A, et al. Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. Metabolites. 2021 May 13;11(5) PubMed PMID: 34068332.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. AU - Scheunemann,Anne, AU - Elsner,Katrin, AU - Germerott,Tanja, AU - Groppa,Sergiu, AU - Hess,Cornelius, AU - Miederer,Isabelle, AU - Poplawski,Alicia, AU - Röhrich,Jörg, Y1 - 2021/05/13/ PY - 2021/04/21/received PY - 2021/05/03/revised PY - 2021/05/07/accepted PY - 2021/6/2/entrez PY - 2021/6/3/pubmed PY - 2021/6/3/medline KW - Dronabinol KW - LC-MS/MS KW - Sativex KW - cannabinoids KW - medical cannabis KW - principal component analysis KW - serum concentrations JF - Metabolites JO - Metabolites VL - 11 IS - 5 N2 - Increasing prescription numbers of cannabis-based medicines raise the question of whether uptake of these medicines can be distinguished from recreational cannabis use. In this pilot study, serum cannabinoid profiles after use of cannabis-based medicines were investigated, in order to identify potential distinguishing markers. Serum samples after use of Sativex®, Dronabinol or medical cannabis were collected and analyzed for 18 different cannabinoids, using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Analytes included delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabicyclol, tetrahydrocannabivarin, cannabidivarin, tetrahydocannabinolic acid A, cannabidiolic acid, cannabinolic acid, cannabigerolic acid, cannabichromenic acid, cannabicyclolic acid, tetrahydrocannabivarinic acid and cannabidivarinic acid. Cannabinoid profiles of study samples were compared to profiles of street cannabis user samples via principal component analysis and Kruskal-Wallis test. Potential distinguishing markers for Dronabinol and Sativex® intake were identified, including 11-hydroxy-tetrahydrocannabinol/delta-9-tetrahydrocannabinol ratios ≥1 and increased concentrations of 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol or cannabichromene. Larger quantities of minor cannabinoids suggested use of cannabis. Use of medical and street cannabis could not be distinguished, except for use of a cannabidiol-rich strain with higher cannabidiol/delta-9-tetrahydrocannabinol and cannabichromene/delta-9-tetrahydrocannabinol ratios. Findings of the study were used to classify forensic serum samples with self-reported use of cannabis-based medicines. SN - 2218-1989 UR - https://www.unboundmedicine.com/medline/citation/34068332/Identification_of_Potential_Distinguishing_Markers_for_the_Use_of_Cannabis_Based_Medicines_or_Street_Cannabis_in_Serum_Samples_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.